New hope for myelofibrosis patients who run out of options
NCT ID NCT07443306
Summary
This study is testing an oral drug called flonoltinib maleate for people with intermediate- or high-risk myelofibrosis, a serious bone marrow cancer, who have already tried and stopped responding to or could not tolerate standard JAK inhibitor drugs. About 64 participants will take the drug daily until they meet withdrawal criteria. The main goal is to see if the drug can shrink enlarged spleens by at least 35% and improve symptoms and survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MF are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.